MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, ZVSA had $455,892 increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$455,892

Unit: Dollar
Cash Flow
2025-09-30
2025-06-30
Non-cash rent expense
-0
Net loss
-19,805,559 -4,468,247
Impairment of in-process research and development
18,647,903 -
Stock-based compensation
73,988 131,490
Depreciation of fixed assets
-0
Issuance of common stock pursuant to vendor agreements
29,600 210,400
Deferred tax (benefit) provision
-851,659 0
Prepaid expenses and other current assets
-80,557 193,876
Accounts payable
314,798 56,208
Operating lease liability
-0
Vendor deposits
-1,652 8,700
Accrued expenses and other current liabilities
105,112 961,545
Net cash used in operating activities
-1,406,912 -3,293,780
Exercise of warrants
-0
Private placement of warrants
0 1,999,791
Warrant inducement offer - exercise proceeds
2,051,852 -
Exercise of pre-funded warrants
0 210
Deferred offering costs
12,511 17,928
Registration and issuance costs associated with warrant issuance
219,487 147,131
Net cash provided by financing activities
1,862,804 1,834,942
Net decrease in cash
455,892 -1,458,838
Cash and cash equivalents at beginning of period
1,530,924 -
Cash and cash equivalents at end of period
527,978 -
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

ZyVersa Therapeutics, Inc. (ZVSA)

ZyVersa Therapeutics, Inc. (ZVSA)